- Report
- July 2022
- 131 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- June 2023
- 159 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- June 2023
- 80 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- April 2023
- 147 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- March 2023
- 147 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- May 2023
- 160 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- February 2024
- 110 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- February 2024
- 117 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- August 2022
- 130 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2023
- 32 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- August 2022
Global
From €751EUR$790USD£631GBP
- Drug Pipelines
- March 2021
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- December 2023
- 182 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- February 2022
- 94 Pages
Global
From €3200EUR$3,606USD£2,782GBP
- Report
- August 2024
- 90 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- August 2024
- 96 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- October 2022
- 94 Pages
Global
From €1901EUR$2,000USD£1,597GBP

Peripheral neuropathy refers to the condition arising from damage to the peripheral nerves, which can lead to weakness, numbness, and pain, typically in the hands and feet, but it can also affect other body parts. The market for peripheral neuropathy within the central nervous system (CNS) drugs segment encompasses a range of therapeutic solutions aimed at alleviating symptoms and slowing the progression of nerve damage. CNS drugs targeting peripheral neuropathy may include anticonvulsants, antidepressants, pain relievers, and other specific medications tailored to address the complex nature of nerve pain and dysfunction.
Treatment strategies focus on underlying causes, symptom control, and improving the quality of life for patients. Innovations in this sector often involve developing new drug formulations, repurposing existing CNS drugs with potential efficacy for neuropathy, and exploring the mechanisms of nerve regeneration and protection. Research and development in this area are ongoing to better understand the intricate biology of the peripheral nervous system and to provide more effective treatments for patients suffering from this debilitating condition.
In the market for peripheral neuropathy treatments, several pharmaceutical and biotech companies are prominent. Pfizer Inc. and Eli Lilly and Company are known for their portfolios that include treatments for neuropathic pain. Other key players like Johnson & Johnson and GlaxoSmithKline PLC have developed and marketed drugs that serve patients with this condition. Additionally, smaller companies and startups, such as NeuroMetrix, Inc., and Regenacy Pharmaceuticals, LLC, focus on innovation and the development of Show Less Read more